Knowledge Center

Article / Jun 08, 2009

The View From New Jersey

Authors:
Source:
C&EN, 8 June, 2009

In the spring of 2003, ËÄÉ«AV opened a small-scale production facility in East Windsor, N.J. As its name implies, the $20 million Technology Transfer Center was intended as a place to develop customers' molecules before moving them to headquarters in Loures, Portugal, for scale-up. Given ËÄÉ«AV's target market of small to midsized drug companies, TTC was meant to boost business with U.S. biotech firms.

Related links

Also in the Knowledge Center

Related Content

Dry Powder Inhalation formulation development

ËÄÉ«AV has considerable inhalation experience that allows us to implement strategies including conventional carrier based, neat (drug-alone) or composite particle formulations.

Page
Read more

Drug Product Development

Leveraging our expertise particle engineering, ËÄÉ«AV can now develop oral dosage forms and inhaled dosages forms to offer dependable solutions for complex drug products.

Page
Read more

Continuous Tableting - Virtual Visit

Welcome to the future of drug product development

Page
Read more